Effect of genistein and raloxifene on vascular dependent platelet aggregation

Molecular and Cellular Endocrinology

Volumn 267, Issue 1-2, 2007, Pages 55-62

  Polini, Nélida ^a   Rauschemberger, María Belén ^a,b   Mendiberri, Josefina ^a,b   Selles, Juana ^a   Massheimer, Virginia ^a,b  

^a UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Genistein; Nitric oxide; Platelet aggregation; Prostacyclin; Raloxifene

Indexed keywords

FULVESTRANT; GENISTEIN; NITRIC OXIDE; PHOSPHOLIPASE A2; PHYTOESTROGEN; PROSTACYCLIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA STRIP; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME RELEASE; FEMALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; THROMBOCYTE AGGREGATION; VASCULAR TISSUE;

ADENOSINE DIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; AORTA; EICOSANOIDS; ESTRADIOL; FEMALE; GENISTEIN; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OVARIECTOMY; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RALOXIFENE; RATS; RATS, WISTAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33847308738     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2006.12.037     Document Type: Article

References (53)

1. Adlercreutz H., Markkanen H., and Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 13 (1993) 1209-1210
2. Andersen H.L., Weis J.U., Fjallad B., and Korsgaard N. Effect of acute and long term treatment with 17-beta estradiol on the vasomotor responses in the rat aorta. Br. J. Pharmacol. 126 (1999) 159-168
3. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., and Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262 (1987) 5592-5595
4. Azuma H., Ishikawa M., and Sekisaki S. Endothelium dependent inhibition of platelet aggregation. Br. J. Pharmacol. 88 (1986) 411-415
5. Barnes S. Phytoestrogens and breast cancer. Bailliere's Clin. Endocrinol. Metab. 12 (1998) 559-579
6. Barnes S., Kim H., DarleyUsmar V., Patel R., Xu J., Boersma B., and Luo M. Beyond ER alpha and ER beta: estrogen receptor binding is only part of the isoflavone story. J. Nutr. 130 (2000) 656S-657S
7. Bowden A., Patel V., Brown C., and Boarder M.R. Evidence for requirement of tyrosine phoshorylation in endothelial P2Y-and P2U. purinoceptor stimulation of prostacyclin release. Br. J. Pharmcol. 116 (1995) 2563-2568
8. Braunwald E. Shattuck lecture: cardiovascular medicine at the turn of the millennium triumphs, concerns, and opportunities. New Engl. J. Med. 337 (1997) 1360-1369
9. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
10. Case J., and Davison C. Estrogen alters relative contributions of nitric oxide and cyclooxygenase products to endothelium-dependent vasodilation. J. Pharmacol. Exp. Ther. 291 (1999) 524-530
11. Chambliss K., and Shaul P. Estrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 23 (2002) 665-686
12. Chen Z., Yuhanna I., Galcheva-Gargova Z., Karas R., Mendelsohn M., and Shaul P. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Investig. 103 (1999) 401-406
13. Czock D., Keller F., Heringa M., and Rasche F. Raloxifene pharmacokinetics in males with normal and impaired renal function. Br. J. Clin. Pharmacol. 59 (2004) 479-482
14. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., and Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl. J. Med. 337 (1997) 1641-1647
15. 2 in the aging process of intestinal cells. J. Cell. Biochem. 93 (2004) 312-326
16. Gottstein N., Ewins B., Eccleston C., Hubbard G., Kavanagh I., Minihane A., Weinberg P., and Rimbach G. Effect of genistein and daidzein on platelet aggregation and monocyte and endothelial function. Br. J. Nutr. 89 (2003) 607-615
17. Grodstein F., Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Joffe M., Rosner B., Fuchs C., Hankinson S.E., Hunter D.J., Hennekens C.H., and Speizer F.E. Postmenopausal hormone therapy and mortality. New Engl. J. Med. 336 (1997) 1769-1775
18. Gryglewski R.J., Palmer R.M.J., and Moncada S. Superoxide anion is involved in the breakdown of endothelium derived vascular relaxing factor. Nature 320 (1986) 454-456
19. Haynes W., and Webb D. Endothelin as a regulator of cardiovascular function in health and disease. J. Hypertens. 16 (1998) 1081-1098
20. Heringa M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int. J. Clin. Pharmacol. Therapeut. 41 (2003) 331-345
21. Hulley S., Grady D., Bush T., Furberg C., Harrington D., Riggs B., and Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS). The J. Am. Med. Assoc. 280 (1998) 605-613
22. Hwang J.L., Hodis H.N., and Sevanian A. Soy and alfalfa phytoestrogen extracts become potent low-density lipoprotein antioxidants in the presence of acerola cherry extract. J. Agric. Food Chem. 49 (2001) 308-314
23. Ignaro L.J. Biological actions and properties of endothelium derived nitric oxide formed and released from artery and vein. Circulat. Res. 65 (1989) 1-21
24. Ignarro L., Cirino G., Casini A., and Napoli C. Nitric oxide as a signalling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 34 (1999) 879-886
25. Kikuta K., Sawamura T., Miwa S., Hashimoto N., and Masaki T. High affinity arginine transport of bovine aortic endothelial cells is impaired by lysophosphatidylcholine. Circulat. Res. 83 (1998) 1088-1096
26. Kuiper G.J.M., Carlsson B., Grandien K., Enmark E., Hagglad J., Nilsson S., and Gustafsson J. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138 (1997) 863-870
27. Li H., Wang L., and Qu S. Phytoestrogen genistein decreases contractile response of aortic artery in vitro and arterial blood pressure in vivo. Acta Pharmacol. Sinica 25 3 (2004) 313-318
28. Liao J.K. Endothelium and acute coronary syndromes. Clin. Chem. 8 44 (1998) 1799-1808
29. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 195 (1951) 265-277
30. Massheimer V., Polini N., Alvarez C., Benozzi S., and Sellés J. 17 Betaestradiol rapid stimulation of rat aorta NOS activity is prevented by oestrogen deficiency. Maturitas 43 (2002) 55-64
31. Massheimer V., Polini N., Alvarez C., Benozzi C., and Selles J. Signal transduction pathways involved in non genomic action of estrona on vascular tissue. Steroids 71 (2006) 857-864
32. Mendelshon M., and Karas R. The protective effects of estrogen on the cardiovascular system. The New Engl. J. Med. 340 (1999) 1801-1811
33. Mendiberri J., Rauschemberger M.B., Sellés J., and Massheimer V. Signal transduction pathways involved in non genomic action of progesterone in rat aortic tissue. Int. J. Biochem. Cell. Biol. 38 2 (2006) 288-296
34. Mitlak B.H., and Cohen F.J. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm. Res. 48 (1997) 155-163
35. Mori-Abe A., Tsutsumi S., Takahashi K., Toya M., Yoshida M., Du B., Kawagoe J., Nakahara K., Takahashi T., Ohmichi M., and Kurachi H. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J. Endocrinol. 178 (2003) 417-426
36. Nabulsi A.A., Folsoni A.R., White A., Patsch W., Heiss G., Wu K.K., Szklo M., and The Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. New Engl. J. Med. 328 (1993) 1069-1075
37. Nakaya M., Tachibana H., and Yamada K. Isoflavone genistein and daidzein up-regulate LPS-induced inducible nitric oxide synthase activity through estrogen receptor pathway in RAW264.7 cells. Biochem. Pharmacol. 71 (2005) 108-114
38. Orshal J., and Khalil R. Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286 (2004) R233-R249
39. Reinli K., and Block G. Phytoestrogen content of foods-a compedium of literature values. Nutr. Cancer 26 (1996) 123-148
40. Rimbach G., Weinberg P.D., Pascual-Teresa S., Alonso M.G., Ewins B.A., Turner R., Minihane A.M., Botting N., Fairley B., Matsugo S., Uchida Y., and Cassidy A. Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function. Biochim. Biophys. Acta 1670 (2004) 229-237
41. Ross R. Atherosclerosis, an inflammatory disease. New Engl. J. Med. 340 (1999) 115-126
42. Salmon J., and Flower R. Extraction and Thin layer Chromatography of arachidonic acid metabolites. Meth. Enzymol. 86 (1982), Academic Press, New York pp. 477-493
43. Sellés J., Polini N., Alvarez C., and Massheimer V. Progesterone and 17 beta-estradiol acutely stimulate nitric oxide synthase activity in rat aorta and inhibit platelet aggregation. Life Sci. 69 (2001) 815-827
44. Sellés J., Polini N., Alvarez C., and Massheimer V. Non genomic actino of progesterone in rat aorta: role of nitric oxide and prostaglandins. Cell. Signal. 14 5 (2002) 431-436
45. Sellés J., Polini N., Alvarez C., and Massheimer V. Novel action of estrone on vascular tissue: regulation of NOS and COX activity. Steroids 70 (2005) 251-256
46. Simon J.A., Hsia J., Cauley J.A., Richards C., Harris F., Fong J., Barrett-Connors E., and Hulley S.B. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 103 (2001) 638-642
47. Simoncini T., and Genazzani A.R. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J. Clin. Endocrinol. Metab. 85 8 (2000) 2966-2969
48. Simoncini T., Genazzani A.R., and Liao J.K. Nongenomic mechanisms of endotelial nitric oxide synthase activation by the selective estrogen rceptor modulator raloxifene. Circulation 19 (2002) 1368-1373
49. Scott J.A., Camara C.C., and Early J.E. Raloxifene: a selective estrogen receptor modulator. Am. Fam. Physician 60 4 (1999) 1131-1139
50. Walker H.A., Dean T.S., Sanders T.A.B., Jackson G., Ritter J.M., and Chowienczyk P.J. The Phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17 β-estradiol. Circulation 16 (2001) 258-262
51. Wang X., Clubbs E., and Bomser J. Genistein modulates prostate epithelial cell proliferation via estrogen-and extracellular signal-regulated kinase-dependent pathways. J. Nutr. Biochem. 17 (2006) 204-210
52. Wheeler-Jones C.P., May M.J., Morgan A.J., and Pearson J.D. Protein tyrosine kinases regulate agonist-stimulated prostacyclin release by not von Willebrand factor secretion form human umbilical vein endothelial cells. Biochem. J. 315 (1996) 407-416
53. Wise H., Wong Y., and Jones R. Prostanoid signal integration and cross talk. Neurosignals 11 (2002) 20-28